Learn languages naturally with fresh, real content!

Popular Topics
Explore By Region
Zelluna ASA, a cancer therapy firm, executes a 10:1 reverse share split, adjusting shares post-transfer.
Zelluna ASA, a cancer treatment company focusing on 'off the shelf' TCR-NK cell therapies, has announced a reverse share split at a 10:1 ratio.
Radforsk Investeringsstiftelse, linked to the company’s board chair, Anders Tuv, transferred 1,730 shares to DNB Bank ASA to ensure all shares are rounded up to the nearest whole share.
The company is scheduled to host an annual general meeting on April 29, 2025.
3 Articles
Zelluna ASA, una firma de terapia contra el cáncer, ejecuta una división de acciones inversa de 10:1, ajustando las acciones después de la transferencia.